The component analysis reflected that among antiplatelets the use of ASA, cilostazol, dipyridamole, and the P2Y12 blocker clopidogrel, ticlopidine, and ticagrelor conveyed a significant reduction of stroke risk. The gene discussed is P2RY12; the disease is stroke disorder.